AgroSpectrum ASIA
Envisaging Future | Updating Present

Aurora and MedReleaf Australia to strengthen medical cannabis supply chain

13 April 2023 | News

Launches IndiMed Tempo 26 through MedReleaf's Concession Scheme, doctors and patients will have more freedom in choosing their cannabis medication



Launches IndiMed Tempo 26 through MedReleaf's Concession Scheme, doctors and patients will have more freedom in choosing their cannabis medication

Aurora Cannabis Inc., the Canadian cannabis company, and MedReleaf Australia have launched IndiMed Tempo 26, a range of premium high THC dried cannabis products for qualified patients under the MedReleaf Concession Scheme (MCS).

Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wide range of options for medical cannabis patients.

"We are proud to further expand the variety of high-quality medical cannabis products Australian patients can access through the MedReleaf Concession Scheme. With the addition of Tempo 26, doctors and patients now have more control and choice about their medical cannabis treatment than ever before. We are committed to our patient-first approach to cannabis and ensuring access to medical patients, in Australia, and around the world" says Miguel Martin, CEO of Aurora Cannabis.

The MCS was developed by MedReleaf Australia and Aurora to provide high-quality products and enhance patient access to medical cannabis, which is not covered by the Pharmaceutical Benefits Scheme (PBS). Through the MCS, patients can access compassionate pricing, specifically for those with Pensioner Concession Cards, Commonwealth Seniors Health Cards, Health Care Cards, and Veterans Cards (DVA).

"These products are cultivated and manufactured in Aurora's GMP-accredited facilities and are made available for doctors to prescribe via the TGA's Special Access Scheme. Through the investment of Aurora and MedReleaf Australia, we have been

able to provide heavily discounted products via our MedReleaf Concession Scheme, which widens the choice for prescriptions and significantly improves access for disadvantaged Australian patients struggling with debilitating health conditions," says Russell Harding, MedReleaf CEO.

Aurora currently holds a 10% ownership stake in MedReleaf Australia, a fully licensed, private company. Together, they provide Australian patients with several innovative, Aurora-branded products, including dried flower, oils, soft gels, and resin cartridges.